Ensysce Biosciences, Inc. ENSC
Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a pain/anesthesia drug developer. Its lead program, PF614, is in Phase 3 for Severe/chronic pain (abuse-resistant TAAP oxycodone prodrug).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PF614 (TAAP oxycodone prodrug) | Severe pain | small molecule | Phase 3 |
| PF614-MPAR | Severe pain with overdose protection | small molecule | Phase 1 |
| Nafamostat | Chronic pain / opioid-related (Phase 1 completed) | small molecule | Phase 1 |
| Cy Biopharma lead candidate (acquired Aug 2026) | Complex Regional Pain Syndrome Type 1 (orphan drug designation) | unclear | Pre-clinical |
Recent results and decisions
- Oct 16, 2026started Phase 2 trial of CY200 for CRPS Type 1 is planned as a randomized, double-blind, placebo-controlled trial in the United Kingdom, with no participant enrolled as of the filing date.
The Phase 2 trial is planned as a randomized, double-blind, placebo-controlled trial with four groups, each receiving two doses three weeks apart: placebo and placebo; 10 mg and placebo; 25 mg and placebo; and 25 mg and 25 mg. The trial is designed to randomize approximately 130 participants so that
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 pain/anesthesia companies
- Mesoblast Ltd MESO
- Latigo Therapeutics, Inc. LTGO
- Anika Therapeutics, Inc. ANIK
- Scilex Holding Co SCLX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.